Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2013. The report specifically addresses the notification of transactions involving Persons Discharging Managerial Responsibility (PDMR) in the company's Ordinary shares, as required under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding executive compensation vesting rather than a financial performance report.
Material Changes
The material change reported is the vesting of equity awards for two executives on September 18, 2013, resulting in cash payments on September 20, 2013:
- Mr. D S Redfern: Received a cash payment of 1598.25p per share for 5,376.638 notional Ordinary shares following the vesting of 25% of an award made in 2007.
- Ms. C Thomas: Received a cash payment of 1598.25p per share for 3,360.399 notional Ordinary shares following the vesting of 25% of an award made in 2007.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on business strategy, risks, contingencies, or unusual items. The content is strictly limited to the disclosure of the specific share transactions described above.
Investor Verification Points
- Verify the total cash payout amounts for Mr. Redfern and Ms. Thomas based on the share counts and price per share disclosed.
- Confirm the terms of the GlaxoSmithKline Deferred Investment Award Plan regarding the 2007 awards.
- Check subsequent filings for any broader financial performance data for the period ending September 2013, as this 6-K does not contain it.